BIOMAT Database Logo BIOMAT Database Logo

Are high-density lipoprotein genes and their products targets for therapy? 2010

Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses
D055106 Genome-Wide Association Study An analysis comparing the allele frequencies of all available (or a whole GENOME representative set of) polymorphic markers to identify gene candidates or quantitative trait loci associated with a specific organism trait or specific disease or condition. Genome Wide Association Analysis,Genome Wide Association Study,GWA Study,Genome Wide Association Scan,Genome Wide Association Studies,Whole Genome Association Analysis,Whole Genome Association Study,Association Studies, Genome-Wide,Association Study, Genome-Wide,GWA Studies,Genome-Wide Association Studies,Studies, GWA,Studies, Genome-Wide Association,Study, GWA,Study, Genome-Wide Association
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
New targets of high-density lipoprotein therapy.
August 2007, Current opinion in lipidology,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
May 2003, Circulation,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
November 2002, Circulation,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
High Density Lipoprotein (HDL) Modulation Targets.
January 2010, Drugs of the future,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
Plasmalogens and their oxidative degradation products in low and high density lipoprotein.
March 1996, Chemistry and physics of lipids,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
High-density lipoprotein metabolism: potential therapeutic targets.
December 2007, The American journal of cardiology,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy.
February 2015, Cardiovascular drugs and therapy,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis.
September 2000, Current atherosclerosis reports,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
High-density lipoprotein is a nanoparticle, but not all nanoparticles are high-density lipoprotein.
September 2013, Proceedings of the National Academy of Sciences of the United States of America,
Mohammad Mahdi Motazacker, and John J Kastelein, and Jan Albert Kuivenhoven
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
March 2006, Circulation,
Copied contents to your clipboard!